Effect of the Janus kinase inhibitor tofacitinib in the treatment of juvenile scleroderma: A single‐center experience-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effect of the Janus kinase inhibitor tofacitinib in the treatment of juvenile scleroderma: A single‐center experience

Published:2024-08 Issue:8 Volume:27 Page:
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J of Rheum Dis

Author:

Colussi Lara¹,Dagri Arianna²,Pastore Serena³^ORCID,Tommasini Alberto¹³,Pin Alessia³,Taddio Andrea¹³

Affiliation:

1. Department of Medicine, Surgery and Health Sciences University of Trieste Trieste Italy

2. Department of Medicine DAME‐Division of Pediatrics University of Udine Udine Italy

3. Institute for Maternal and Child Health IRCCS “Burlo Garofolo” Trieste Italy

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1756-185X.15295

Reference12 articles.

1. Scleroderma in Children and Adolescents

2. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review

3. The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib

4. JAK inhibitors and systemic sclerosis: A systematic review of the literature

5. Update on management of morphea (Localized Scleroderma) in children

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP